IDH1 and cholangiocarcinoma: The IDH-1 inhibitor ivosidenib was shown to improve PFS versus placebo (2.7 vs. 1.4 months, p < 0.0001) among 124 patients with metastatic IDH1-mutated cholangiocarcinoma in a phase III trial.